Incyte logo

INCY - Incyte News Story

$82.76 0.4  0.5%

Last Trade - 8:25pm

Sector
Healthcare
Size
Large Cap
Market Cap £13.04bn
Enterprise Value £11.65bn
Revenue £1.95bn
Position in Universe 638th / 6854

BRIEF-Lilly And Incyte Announce Results From The Phase 3 Cov-Barrier Study Of Baricitinib In Hospitalized Covid-19 Patients

Fri 16th April, 2021 9:38pm
April 16 (Reuters) - Incyte Corp  INCY.O :
    * LILLY AND INCYTE ANNOUNCE RESULTS FROM THE PHASE 3
COV-BARRIER
STUDY OF BARICITINIB IN HOSPITALIZED COVID-19 PATIENTS
    * INCYTE CORP - TRIAL DID NOT MEET STATISTICAL SIGNIFICANCE
ON
PRIMARY ENDPOINT
    * INCYTE CORP - BARICITINIB-TREATED PATIENTS WERE 2.7 PER
CENT
LESS LIKELY THAN THOSE RECEIVING STANDARD OF CARE TO PROGRESS TO
VENTILATION OR DEATH
    * INCYTE CORP -  FREQUENCY OF ADVERSE EVENTS AND SERIOUS
ADVERSE
EVENTS WERE GENERALLY SIMILAR IN BARICITINIB AND PLACEBO GROUPS
    * INCYTE CORP - NO NEW SAFETY SIGNALS POTENTIALLY RELATED TO
USE
OF BARICITINIB WERE IDENTIFIED

Source text for Eikon:  ID:nCNWCsrrva 
Further company coverage:  INCY.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.